Cormorant Asset Management ORKA Position
Active8-Fund ConvergenceCormorant Asset Management held their position in Oruka Therapeutics, Inc. (ORKA) in Q4 2025, holding $16.2M worth of shares across 533,340 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
ORKA is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for ORKA-001 Induction Dose in 14 days (Apr 30, 2026), making the timing of Cormorant's position particularly relevant.
Short interest stands at 10.3% of float with 9.1 days to cover, indicating significant bearish positioning against Cormorant's long thesis.
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Full company profile →Short Interest
10.3%
9.1 days to cover
Cormorant Asset Management ORKA Position History
Frequently Asked Questions
Does Cormorant Asset Management own ORKA?
Yes. As of Q4 2025, Cormorant Asset Management holds 533,340 shares of Oruka Therapeutics, Inc. (ORKA) valued at $16.2M. This data comes from their SEC 13F filing.
How many hedge funds own ORKA?
8 specialist biotech hedge funds currently hold ORKA, including Deep Track Capital, RTW Investments, Commodore Capital and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Cormorant Asset Management first buy ORKA?
Cormorant Asset Management's position in ORKA was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Cormorant Asset Management's ORKA position increasing or decreasing?
Cormorant Asset Management held their ORKA position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ORKACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Cormorant Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →